SEARCH

SEARCH BY CITATION

References

  • 1
    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:. 23). BMJ. 1998;316: 823828.
  • 2
    Davis TM, Millns H, Stratton IM, et al. Risk factors for stroke in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 29. Arch Intern Med. 1999;159: 10971103.
  • 3
    Maki DD, Ma JZ, Louis TA, et al. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med. 1995;155(10):10731080.
  • 4
    Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321: 412419.
  • 5
    Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351: 17551762.
  • 6
    Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med. 1999;340: 677684.
  • 7
    Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study Group 38. BMJ. 1998;317: 703713.
  • 8
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289: 25602572.
  • 9
    Brown MJ, Castaigne A, de Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35(5):10381042.
  • 10
    Lewis EJ, Hunsicker LG, Clarke WR, et al., For the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345: 851860.
  • 11
    Bakris GL, Gaxiola E, Messerli FH, et al. INVEST Investigators. Clinical outcomes in the diabetes cohort of the International Verapamil SR-Trandolapril study. Hypertension. 2004;44: 637642.
  • 12
    Bakris GL, Weir M.; Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens. (Greenwich). 2003;5(3):202209.
  • 13
    American Diabetes Association. Treatment of Hypertension in Adults With Diabetes. Diab Care. 2003;26(suppl 1): S80S82.
  • 14
    Messerli FH. Combinations in the treatment of hypertension: ACE inhibitors and calcium antagonists. Am J Hypertens. 1999;12(8 pt 2):86S90S.
  • 15
    Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65: 19912002.
  • 16
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. INVEST Investigators. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290: 28052816.
  • 17
    Ruilope LM, Usan L, Segura J, et al. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (Presion Arterial en Diabeticos Tipo Dos) study. J Hypertens. 2004;22: 217222.
  • 18
    Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil-trandolapril treatment in contrast to beta-blocker-low-dose chlorthalidone treatment in hypertensive type 2 diabetes. J Hypertens. 1996;14: 669677.
  • 19
    Holzgreve H, Nakov R, Beck K, et al. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens. 2003;16(5 pt 1):381386.
  • 20
    Fernandez R, Puig JG, Rodriguez-Perez JC, et al. TRAVEND Study Group. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens. 2001;15: 849856.
  • 21
    Rubio-Guerra AF, Arceo-Navarro A, Vargas-Ayala G, et al. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care. 2004;27: 16881691.
  • 22
    Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54: 12831289.
  • 23
    Ruggenenti P, Fassi A, Ilieva AP, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351: 19411951.
  • 24
    Shigihara T, Sato A, Hayashi K, et al. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res. 2000;23: 219226.
  • 25
    Bakris GL, Smith AC, Richardson DJ, et al. Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multicentre pilot study. J Hum Hypertens. 2002;16: 185191.
  • 26
    Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type. diabetic patients. Am J Hypertens. 2002;15: 10421049.
  • 27
    Bakris GL, Toto RD, McCullough PA. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. J Hum Hypertens. 2005;19: 139144.
  • 28
    Kuriyama S, Tomonari H, Tokudome G, et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res. 2002;25: 849855.
  • 29
    Mogensen CE, Viberti G, Halimi S, et al. Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension. 2003;41: 10631071.
  • 30
    ADVANCE Collaborative Group. ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med. 2005;22: 882888.
  • 31
    Krum H, Skiba M, Gilbert RE. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Diabet Med. 2003;20: 708712.
  • 32
    Fox JC, Leight K, Sutradhar SC, et al. The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy. J Clin Hypertens. (Greenwich). 2004;6(8):437442.
  • 33
    Azizi M, Menard J. Combined blockade of the reninangiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109: 24922499.
  • 34
    Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 2000;321: 14401444.
  • 35
    Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care. 2002;25: 95100.
  • 36
    Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant. 2002;17: 10191024.
  • 37
    Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol. 2003;14: 992999.
  • 38
    Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003;63: 18741880.
  • 39
    Rossing K, Jacobsen P, Pietraszek L, et al. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care. 2003;26: 22682274.
  • 40
    Andersen NH, Poulsen PL, Knudsen ST, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care. 2005;28: 273277.